Prevention of acute myocardial damage in elective percutaneous coronary interventions

Data of many researchers suggest that the level of cardiac biomarkers indicating necrosis of cardiomyocytes increases during endovascular procedures on the coronary arteries. The risk of subsequent major cardiac events including death and myocardial infarction is associated with the degree of elevation of cardiac enzymes after surgery. Therefore, therapeutic strategies attenuating the frequency of procedural myocardial injury can have a positive impact on clinical outcomes after endovascular interventions. The authors demonstrated that the use of high loading doses of potent statins (atorvastatin and rosuvastatin) with a planned endovascular coronary intervention in patients who already receive standard lipidlowering therapy long-term, has a similar effect on the dynamics of cardiac biomarkers after PCI. At the same time, administration of a loading dose of rosuvastatin has an advantage due to a significantly smaller increase in the levels of creatine kinase-MB and TnI (26.7% and 27.1%, respectively) during the first 12 hours after the procedure. The second part of the work demonstrates that the addition of trimetazidine to standard therapy in endovascular revascularization in patients with impaired glucose metabolism reduces acute myocardial damage, although the clinical significance of the effect of that protection on remote patient outcomes requires more studies.

ишемическая болезнь сердца, стабильная стенокардия, чрескожные коронарные вмешательства, статины, триметазидин, coronary artery disease, stable angina, percutaneous coronary intervention, statins, trimetazidin

1. Califf R.M., Abdelmeguid A.E., Kunitz R.E. et al. Myonecrosis after revascularization procedures // J. Am. Coll. Cardiol. - 1998. -Vol. 31. - P. 241-251.

2. Klein R.W., Kramer B.L., Howard E., Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty // J. Am. Coll. Cardiol. - 1991. -Vol. 17. - P. 321-326.

3. Prasad A., Herrmann J. Myocardial Infarction due to percutaneous coronary intervention // N. Eng. J. Med. - 2011. - Vol. 364. - P 453-464.

4. Ellis S.G., Chew D., Chan A. et al. Death following creatine kinase-MB elevation after coronary intervention. Identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function and and probable benefit of statin therapy // Circulation. - 2002. -Vol. 106. - P. 1205-1211.

5. Ioannidis J.P.A., Karvouni E., Katritis D.G. Mortality risk conferred by small elevations of creatine-kinase MB isoenzyme after percutaneous intervention // J. Am. Coll. Cardiol. - 2003. -Vol. 42. - P. 1406-1411.

6. Merla R., Reddy N.K., Wang F.W. et al. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on peri-procedural myonecrosis // Am. J. Cardiol. - 2007. - Vol. 100. - P. 770-776.

7. Veselka J., Prochazkova S., Duchnova R. et al. Pre-procedural statin therapy reduces the risk and extent of cardiac biomarkers release following percutaneous coronary intervention // Heart Vessels. - 2006. - Vol. 21. - P. 146-151.

8. Jones S.P., Trocha S.D., Lefer D.J. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion // Arterioscler. Thromb. Vasc. Biol. - 2001. -Vol. 21. - P. 2059-2064.

9. Bell R.M., Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 508-515.

10. Mensah K., Mocanu M.M., Yellon D.M: Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? // J. Am. Coll. Cardiol. - 2005. -Vol. 45. - Р 1287-1291.

11. Wang T., Yang Y.J., Xu B. Atorvastatin pretreatment before PCI accelerates both neointimal coverage and reendothelialization after sirolimus-eluting stent implantation using a porcine model: new findings from optical coherence tomography and pathology // J. Am. Coll. Cardiol. - 2012. - Vol. 59. - P. 1196-1209.

12. Davignon J. Beneficial cardiovascular pleiotropic effects of statins // Circulation. - 2004. - Vol. 109, No. 23, Suppl 1(III). -P. 39-43.

13. Sanguigni V., Pignatelli P., Lenti L. et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients // Circulation. - 2005. - Vol. 111. - P. 412-419.

14. Hinoi T., Matsuo S., Tadehara F. et al. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography // Am. J. Cardiol. - 2005. - Vol. 96. - P. 89-91.

15. Pasceri V., Patti G., Nusca A. et al. ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study // Circulation. - 2004. - Vol. 110. - P. 674-678.

16. Briguori C., Visconti G., Focaccio A. et al. Novel Approches for Preventing or Limiting Events (NAPLES II) trial // J. Am. Coll. Cardiol. - 2009. - Vol. 54. - Р 2157-2163.

17. Sardella G., Conti G., Donahue M. et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial // Catheter Cardiovasc. Interv. - 2013. - No. 81. - Р 36-43.

18. Patti G., Cannon C.P, Murphy S.A. et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention. A collaborative patient-level meta-analysis of 13 randomized study // Circulation. - 2011. - Vol. 123. - Р 1622-1632.

19. Di Sciascio G., Patti G., Pasceri V. et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial // J. Am. Coll. Cardiol. -2009. - No. 54. - Р. 558-565.

20. Sardella G., Lucisano L., Mancone M. et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial [Electronic resource] // Int. J. Cardiol. - 2013. - URL: http://dx.doi.org/10.1016/j.ijcard.2013.06.017 (дата обращения 05.04.2015).

21. Zemanek D., Branny M., Martinkovicova L. et al. Effect of sevenday atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study // Inter. J. of Cardiology. - 2013. -Vol. 168. - P. 2494-2497.

22. Creager M.A., Luscher T.F., Cosentino F. et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy // Circulation. - 2003. - Vol. 108 (12). -P. 1527-1532.

23. Вершинина Е.О., Репин А.Н., Рябова Т.Р. и др. Ближайшие и отдаленные результаты плановых эндоваскулярных вмешательств на коронарных артериях и влияние на них нарушений углеводного обмена // Сибирский медицинский журнал (Томск). - 2013. - Т. 28(4). - С. 28-35.

24. Carrozza J.P., Kuntz R.E., Levine M.J. et al. Angiographic and clinical outcome of intracoronary stenting: immediate and longterm results from a large single-center experience // J. Am. Coll. Cardiol. - 1992. - Vol. 20. - P. 328-337.

25. Ryden L., Grant P.J., Anker S.D. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, prediabetes, and cardiovascular dis-eases of the European Society of Cardiology (ESC) and developed incollaboration with the European Association for the Study of Diabetes (EASD) // Eur. Heart J. - 2013. - Vol. 34. - P. 3035-3087.

26. Moses J.W., Leon M.B., Popma J.J. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery // N. Engl. J. Med. - 2003. - Vol. 349. - P. 1315-1323.

27. Grube E., Silber S., Hauptmann K.E. et al. TAXUS I: six- and twelvemonth results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions // Circulation. - 2003. - Vol. 107. - P. 38-42.

28. Scrutinio D.I., Scrutinio D., Giannuzzi P. et al. Comorbidity in patients undergoing coronary artery bypass graft surgery: impact on outcome and implications for cardiac rehabilitation // European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. - 2008. -Vol. 15. - P 379-385.

29. Balakumar P., Sharma N.K. Healing the diabetic heart: Does myocardial preconditioning work? // Cellular Signalling. - 2011. - Vol. 24. - P 53-59.

30. Дедов И.И., Александров А.А. Диабетическое сердце: основные закономерности // Сердце. - 2004. - № 3(1). - P 5-8.

31. Folli F., Corradi D., Fanti P. et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach // Curr. Diabetes Rev. - 2011. - No. 7. -P. 313-324.

32. Pantos C., Mourouzis I. Protection of the abnormal heart // Heart Fail Rev. - 2007. - No. 12. - P. 319-330.

33. Cokkinos D.V., Pantos С. Myocardial protection in man - from research concept to clinical practice // Heart Fail Rev. - 2007. - No. 12. - P. 345-362.

34. ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр) // Кардиоваскулярная терапия и профилактика. - 2008. - № 7(6), прил. 4. - P. 1-28.

35. Raedschelders K., Ansley D.M., Chen D.D.Y. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion // Pharmacol. Ther. - 2012. - Vol. 133. - P. 230-255.

36. Folli F., Corradi D., Fanti P. et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach // Curr. Diabetes Rev. - 2011. - No. 7. -P. 313-324.

37. Takayanagi R., Inoguchi T., Ohnaka K. Clinical and experimental evidence for oxidative stress as an exacerbating factor of diabetes mellitus // J. Clin. Biochem. Nutr. - 2011. - No. 48. -P. 72-77.

38. Kantor P.F., Lucien A., Kozak R. et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase // Circ. Res. - 2000. - No. 86. - P. 580-588.

39. Ikizler M., Erkasap N., Dernek S. et al. Trimetazidine-induced enhancement of myocardial recovery during reperfusion: a comparative study in diabetic and non-diabetic rat hearts // Arch. Med. Res. - 2006. - Vol. 37(6). - P. 700-708.

40. Люсов В.А., Волов Н.А., Гордеев И.Г. и др. Роль миокардиальной цитопротекции в коррекции ишемического и реперфузионного повреждения миокарда у больных стабильной стенокардией, перенесших транслюминальную баллонную ангиопластику и стентирование коронарных артерий // Рос. кардиол. журнал. - 2006. - № 1. - P 33-38.

41. Bonello L., Sbragia P., Amabile N. et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention // Heart. - 2007. - Vol. 93. - P. 703-707.

42. Iskesen I., Kurdal A.T., Eserdag M. et al. Trimetazidine may protect the myocardium during cardiac surgery // Heart Surg. Forum. -2009. - No. 12. - P. 175-179.

43. Labrou A., Giannoglou G., Ziotas D. et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention // Am. J. Cardiovasc. Drugs. - 2007. - No. 7. - P. 143-150.